European Commission approves Duzallo to treat gout.- Grunenthal.
Grünenthall announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo (lesinurad + allopurinol) marketing authorization for the EU/EEA.
Duzallo is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years. |
Comment; Grünenthal's first gout product Zurampic was launched in Switzerland and Italy. By the end of this year, it will have been launched in other European countries. Duzallo is planned to be launched in most European countries in 2019..
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins